日韩精品久久无码中文字幕,青青草视频下载,一区二区在线观看电影院,一色屋精品视频在线观看

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人:蔣經(jīng)理
電話:4008750250
號碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73191SLC34A2-ROS1/BaF3

SLC34A2-ROS1/BaF3
名稱 SLC34A2-ROS1/BaF3
型號 CBP73191
報價
特點 SLC34A2-ROS1/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO;
  • 詳細(xì)內(nèi)容
CBP73191
I. Introduction

Cell Line Name:

SLC34A2-ROS1/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Approximately 2% of lung tumors harbor ROS1 fusions (Bergethon et al. 2012). Like ALK fusions, ROS1 fusions are more commonly found in light smokers (<10 pack years) and/or never-smokers. ROS1 fusions are also associated with younger age and adenocarcinomas (Bergethon et al. 2012).

In preclinical models, ROS1 fusions are associated with sensitivity to tyrosine kinase inhibitors that have 'off-target' activity against ROS1, such as crizotinib (Bergethon et al. 2012; Davies et al. 2012). In addition, two patients—a previously treated metastatic NSCLC patient and a 65-year-old never smoker NSCLC patient—with tumors harboring ROS1 fusions have had partial responses to crizotinib (Bergethon et al. 2012; Davies et al. 2012). In an expansion cohort of a phase I study, 50 patients with ROS1-positive NSCLC demonstrated a 72% response rate and 19.2-month median progression-free survival interval when treated with crizotinib (Ou et al. 2013; Shaw et al. 2014). In a European case study, 32 ROS1-positive NSCLC cases treated with crizotinib were retrospectively reviewed, and an 80% response rate and a 9.1-month median progression-free survival interval was calculated in this cohort (Mazières et al. 2015).

Several different ROS1 rearrangements have been described in NSCLC. These include SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1, and SDC4-ROS1 (Figure 1; Davies et al. 2012; Rikova et al. 2007; Takeuchi et al. 2012). Clinically, the presence of a ROS1 rearrangement is detected by fluorescence in situ hybridization (FISH) with a ROS1 breakapart probe. FISH testing is not able to discern which particular ROS1 fusion is found in a clinical sample.

ROS1 rearrangements are non-overlapping with other oncogenic mutations found in NSCLC (e.g., EGFR mutations, KRAS mutations, ALK fusions, etc.; Bergethon et al. 2012).


III. Representative Data

1. WB of SLC34A2-ROS1 expression

CBP73191 WB.png



2.Sanger Sequencing of SLC34A2-ROS1 Fusion

CBP73191 sanger.png

2. Anti-proliferation assay

CBP73191 fig.png

Figure 3. Anti-proliferation assay of two reference compounds on the SLC34A2-ROS1/BaF3 Stable Cell Line.


如果你對CBP73191SLC34A2-ROS1/BaF3感興趣,想了解更詳細(xì)的產(chǎn)品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說明:

  • 驗證碼:

    請輸入計算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
男人添女人下部高潮视频| 国产精品肉丝袜久久久久| 国产在线视频欧美亚综合| 亚洲第一天堂| 996精品视频在线观看| 电信的卡没信号怎么回事| 国产无遮挡在线播放视频| 一区二区三区avsex| 部长与人妻日本中字在线| 国产三级在线视频免费观看| 肏少妇屄视频网站交换肏| 亚洲精品扒开跟做爽爽爽| 国产免费久久精品久久久| 九九热这里只有黄色精品| 久久亚洲精品无码爱剪辑| 国产羞辱调教无码的视频| 国内精品久久久久久TV| 夜夜操天天操天天操天天操| 免费亚洲黄色正在热播放| 啊啊啊好疼黄片好大啊啊| 啊啊啊别肏了,好痛动漫| 亚洲熟女50p| 亚洲A视频免费看十分钟| 91麻豆产精品久久久久久| 国产精品永久久久久久久| 操死你插骚逼插男同视频| 动物鸡把操女人小穴电视| 久久午夜张柏芝| 另类男人的天堂| 国产白嫩大屁股免费视频| 亚洲一区二区丝袜美腿人妻| 国产九色porny91| 国产特级黄片高清在线看| 少妇喷奶水中文字幕有码| 出租屋嫖妓熟女| 美女少妇裸体AA级AA| 精品人妻少妇av免费看| 久久久这里有精品999| 色女人网免费的| 啊啊啊嗯嗯不要视频在线| 淫荡的人妻视频|